Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1987 Sep;62(9):905–911. doi: 10.1136/adc.62.9.905

Prospective study of serum staphylococcal antibodies in cystic fibrosis.

A E Hollsing 1, M Granström 1, B Strandvik 1
PMCID: PMC1778603  PMID: 3118820

Abstract

Serum IgG antibodies to teichoic acid and alpha toxin from Staphylococcus aureus were measured in 62 patients with cystic fibrosis by enzyme linked immunosorbent assays. The patients were followed up for 12-24 months in a prospective study. Raised titres were found exclusively in patients chronically colonised with S aureus. Patients colonised with both S aureus and Pseudomonas aeruginosa had significantly higher titres against teichoic acid than those carrying S aureus alone. Titres were significantly higher when there were clinical signs of low grade infection in the patients chronically colonised with S aureus alone, and in those with both S aureus and P aeruginosa. Significant reduction in titres occurred after antimicrobial treatment given either orally or intravenously in patients with normal erythrocyte sedimentation rates and white cell counts. Measurement of staphylococcal antibody titres may be valuable in monitoring pulmonary infection and antimicrobial treatment in patients with cystic fibrosis.

Full text

PDF
910

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ericsson A., Granström M., Möllby R., Strandvik B. Antibodies to staphylococcal teichoic acid and alpha toxin in patients with cystic fibrosis. Acta Paediatr Scand. 1986 Jan;75(1):139–144. doi: 10.1111/j.1651-2227.1986.tb10170.x. [DOI] [PubMed] [Google Scholar]
  2. Granström M., Julander I. G., Hedström S. A., Möllby R. Enzyme-linked immunosorbent assay for antibodies against teichoic acid in patients with staphylococcal infections. J Clin Microbiol. 1983 Apr;17(4):640–646. doi: 10.1128/jcm.17.4.640-646.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Granström M., Julander I., Möllby R. Serological diagnosis of deep Staphylococcus aureus infections by enzyme-linked immunosorbent assay (ELISA) for staphylococcal hemolysins and teichoic acid. Scand J Infect Dis Suppl. 1983;41:132–139. [PubMed] [Google Scholar]
  4. ILLINGWORTH R. S. Cyanotic attacks in newborn infants. Arch Dis Child. 1957 Aug;32(164):328–332. doi: 10.1136/adc.32.164.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Julander I. G., Granström M., Hedström S. A., Möllby R. The role of antibodies against alpha-toxin and teichoic acid in the diagnosis of staphylococcal infections. Infection. 1983 Mar-Apr;11(2):77–83. doi: 10.1007/BF01641071. [DOI] [PubMed] [Google Scholar]
  6. Kelly H. W., Lovato C. Antibiotic use in cystic fibrosis. Drug Intell Clin Pharm. 1984 Oct;18(10):772–783. doi: 10.1177/106002808401801001. [DOI] [PubMed] [Google Scholar]
  7. Kulczycki L. L., Murphy T. M., Bellanti J. A. Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA. 1978 Jul 7;240(1):30–34. [PubMed] [Google Scholar]
  8. Kusoffsky E., Strandvik B., Troell S. Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1983;2(3):434–438. doi: 10.1097/00005176-198302030-00007. [DOI] [PubMed] [Google Scholar]
  9. Marks M. I. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981 Feb;98(2):173–179. doi: 10.1016/s0022-3476(81)80631-2. [DOI] [PubMed] [Google Scholar]
  10. Matthews L. W., Drotar D. Cystic fibrosis--a challenging long-term chronic disease. Pediatr Clin North Am. 1984 Feb;31(1):133–152. doi: 10.1016/s0031-3955(16)34541-2. [DOI] [PubMed] [Google Scholar]
  11. Nelson J. D. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. J Pediatr. 1985 Jun;106(6):1030–1034. doi: 10.1016/s0022-3476(85)80264-x. [DOI] [PubMed] [Google Scholar]
  12. Pier G. B. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction. J Infect Dis. 1985 Apr;151(4):575–580. doi: 10.1093/infdis/151.4.575. [DOI] [PubMed] [Google Scholar]
  13. SHWACHMAN H., FEKETE E., KULCZYCKI L. L., FOLEY G. E. The effect of long-term antibiotic therapy in patients with cystic fibrosis of the pancreas. Antibiot Annu. 1958;6:692–699. [PubMed] [Google Scholar]
  14. SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
  15. Strandvik B., Malmborg A. S., Alfredson H., Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):283–287. doi: 10.1093/jac/12.suppl_a.283. [DOI] [PubMed] [Google Scholar]
  16. Szaff M., Høiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr Scand. 1982 Sep;71(5):821–826. doi: 10.1111/j.1651-2227.1982.tb09526.x. [DOI] [PubMed] [Google Scholar]
  17. Verbrugh H. A., Peters R., Goessens W. H., Michel M. F. Distinguishing complicated from uncomplicated bacteremia caused by Staphylococcus aureus: the value of "new" and "old" serological tests. J Infect Dis. 1986 Jan;153(1):109–115. doi: 10.1093/infdis/153.1.109. [DOI] [PubMed] [Google Scholar]
  18. Wheat L. J., Kohler R. B., White A. Solid-phase radioimmunoassay for immunoglobulin G Staphylococcus aureus antibody in serious staphylococcal infection. Ann Intern Med. 1978 Oct;89(4):467–472. doi: 10.7326/0003-4819-89-4-467. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES